Skip to content
IV Injection Allopathic

Vabysmo 6 mg/0.05 ml iv injection

Generic: Faricimab

Company: Roche Bangladesh Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength6 mg/0.05 ml
PackNot listed yet

Reviewed by: not listed yet. Source: not listed yet.

Last updated November 1, 2025.

Compare

Same generic, same strength

Sorted by price per iv injection. Ask your pharmacist before you switch brands.

Faricimab 6 mg/0.05 ml iv injections

Prices as listed on BestinMeds.

No price is listed for this strength yet.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Faricimab guide

Indications

Faricimab is a bispecific angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of: Neovascular (wet) age-related macular degeneration (nAMD) Diabetic macular edema (DME) Macular edema secondary to retinal vein occlusion (RVO)

Dosage and administration

General: For intravitreal injection only. VABYSMO must be administered by a qualified physician experienced in intravitreal injections. Each vial should only be used for the treatment of a single eye. Neovascular (wet) age-related macular degeneration (nAMD): The recommended dose for VABYSMO is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 4 doses, followed by 6 mg (0.05 mL) via intravitreal injection at a dosing interval of up to every 16 weeks (4 months). Monitoring between the dosing visits should be scheduled based on the patient's status and at the physician's discretion. Diabetic macular edema (DME): The recommended dose for VABYSMO is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly) for the first 4 doses, followed by 6 mg (0.05 mL) via intravitreal injection at intervals of up to every 16 weeks (4 months). Monitoring between the dosing visits should be scheduled based on the patient's status and at the physician's discretion. Macular edema secondary to retinal vein occlusion (RVO): The recommended dose for VABYSMO is 6 mg (0.05 mL) administered by intravitreal injection every 4 weeks (monthly). Monitoring between the dosing visits should be scheduled based on the patient’s status and at the physician’s discretion.

Side effects

This information is not available. Ask your doctor or pharmacist.

Precautions and warnings

This information is not available. Ask your doctor or pharmacist.

Pregnancy and lactation

There are no data from the use of Faricimab in pregnant women. It is not known whether Faricimab is excreted in human breast milk. No studies have been conducted to assess the impact of Faricimabon milk production or its presence in breast milk.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250